Cytarabine and venetoclax for older adults with AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 75 years old.
- You have a type of AML (acute myeloid leukemia) that is not acute promyelocytic leukemia.
- Your leukemia is classified as intermediate or high risk by the 2022 ELN guidelines.
- You have achieved remission (no leukemia cells in your bone marrow) after your first treatment.
- You are not eligible for a stem cell transplant.
- Your liver and kidney function are within an acceptable range, and your heart is working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a second drug (venetoclax) to a standard chemotherapy (azacitidine) works better than the standard alone for adults aged 60 to 75 with newly diagnosed acute myeloid leukemia (AML).
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This study tests a combination of two oral and IV medicines (venetoclax and decitabine) for older adults or people who cannot receive strong chemotherapy for newly diagnosed acute myeloid leukemia (AML). The goal is to see if this gentler treatment can help control the disease with fewer side effects.
This trial tests a combination of four drugs (venetoclax, azacitidine, chidamide, and CAG chemotherapy) to treat newly diagnosed acute myeloid leukemia (AML—a blood cancer) in adults aged 60–75. The goal is to see if this combination helps patients live longer and feel better.
This trial tests a combination of three drugs – venetoclax, cytarabine, and metformin – for adults with AML who cannot receive standard high-dose chemotherapy. It aims to see if this gentler mix can help control the leukemia with fewer side effects.
This trial studies a two-part chemotherapy plan for older adults newly diagnosed with acute myeloid leukemia (AML) who can’t take the usual standard induction treatment. It aims to improve how well treatment works while taking into account age and other health conditions.
Hear when a new Elderly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.